Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barré syndrome

PLoS ONE

Volumn 3, Issue 5, 2008, Pages

  Mori, Izumi ^a,c   Parizot, Cristophe ^b   Dorgham, Karim ^a   Demeret, Sophie ^b   Amoura, Zahir ^b,c   Bolgert, Francis ^b   Gorochov, Guy ^a,b,c  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PREDNISOLONE; SYNDECAN 1;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CELL COUNT; CELL MATURATION; CELL MOTILITY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN CELL; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; MYOSITIS; OUTCOME ASSESSMENT; PATIENT MONITORING; PILOT STUDY; PLASMA CELL; PLASMACYTOSIS; PLASMAPHERESIS; PNEUMONIA; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SEPTICEMIA; CELL SURVIVAL; CYTOLOGY; DRUG EFFECT; HOSPITALIZATION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; REFERENCE VALUE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL SURVIVAL; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PLASMA CELLS; REFERENCE VALUES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 47749090555     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002109     Document Type: Article

References (35)

1. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345: 747-755.
2. Gürcan HM (2007) Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Ann Pharmacother 41: 812-823.
3. Govoni V, Granieri E (2001) Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol 14: 605-613.
4. Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der Meché FG (1999) Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology 53: 598-604.
5. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, et al. (2007) A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 6: 589-594.
6. van der Meché FG: Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 326: 1123-1129.
7. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (1997) Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrcqne. Lancet 349: 225-230.
8. Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27 Suppl. pp S21-24.
9. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force (1991) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 41: 617-618.
10. Victor M, Ropper AH (2001) Myasthenia gravis and related disorders of the neuromuscular junction. In; Victor M, Ropper AH, eds. Adams and Victor's principles of neurology (7th ed) McGraw-Hill Inc: New York, pp 1536-1539.
11. Bohan A, Peter JB, Bowman RL, Pearson CM (1977) Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 56: 255-286.
12. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2: 750-753.
13. Klein U, Rajewsky K, Kuppers R (1998) Human immunoglobulin (Ig)M+IgD+peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 188: 1679-1689.
14. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, et al. (2000) Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165: 5970-5979.
15. Odendahl M, Mei H, Hoyer BF, Jacobi AM, Hansen A, et al. (2005) Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105: 1614-1621.
16. Medina F, Segundo C, Campos-Caro A, Gonzalez-Garcia I, Brieva. JA (2002) The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 99: 2154-2161.
17. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, et al. (2003) Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 170: 1136-1140.
18. Muehlinghaus G, Cigliano L, Huehn S, Peddinghaus A, Leyendeckers H, et al. (2005) Regulation of CX-CR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 105: 3965-3971.
19. Thomson PD, Harris NS (1977) Detection of plaque-forming cells in the peripheral blood of actively immunized humans. J Immunol 118: 1480-1482.
20. Stevens RHME, Morrow C, Saxon A (1979) Characterization of a circulating subpopulation of spontaneous antitetanus antibody producing cells following in vivo booster immunization. J Immunol 122: 2498-2504.
21. Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, et al. (2005) Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128: 1667-1676.
22. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, et al. (2004) Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci U S A 101: 11404-11409.
23. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, et al. (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6: 741-750.
24. Bernasconi NL, Traggiai E, Lanzavecchia A (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298: 2199-2202.
25. Siragam V, Crow AR, Brinc D, Song S, Freedman J, et al. (2006) Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12: 688-692.
26. Nimmerjahn F, Ravetch JV (2007) The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 204: 11-15.
27. Gold P, Stangel M, Dalakas MC (2007) Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 3: 36-44.
28. Xiang Z, Cutler AJ, Brownlie RJ, Fairfax K, Lawlor KE, et al. (2007) FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol 8: 419-429.
29. Ravetch JV, Nussenzweig M (2007) Killing some to make way for others. Nat Immunol 8: 337-339.
30. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, et al. (2004) Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 199: 1577-1584.
31. Guillain-Barré Syndrome Steroid Trial Group (1993) Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome, Lancet 341: 586-590.
32. van Koningsveld R, Schmitz PI, van der Meché FG, Visser LH, Meulstee J, et al. (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomized trial. Lancet 363: 192-196.
33. Ahmed AR (2004) Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy. Expert Opin Investig Drugs 13: 1019-1032.
34. de Grandmont MJ, Racine C, Roy A, Lemieux R, Neron S (2003) Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 101: 3065-3073.
35. Vassilev T, Yamamoto M, Aissaoui A, Bonnin E, Berrih-Aknin S, et al. (1999) Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur J Immunol 29: 2436-2442.